COVID-19: Analysis of Drug Repositioning Practice

An outbreak of a new coronavirus disease (COVID-19) in China in December 2019 became the epicenter for the spread of a global pandemic. The SARS-CoV-2 coronavirus causes a cascade of respiratory diseases similar to severe acute respiratory syndrome (SARS). Currently, there is no effective, specific,...

Descripción completa

Detalles Bibliográficos
Autores principales: Savosina, P. I., Druzhilovskii, D. S., Poroikov, V. V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Search for New Drugs
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7797491/
https://www.ncbi.nlm.nih.gov/pubmed/33456092
http://dx.doi.org/10.1007/s11094-021-02308-0
Descripción
Sumario:An outbreak of a new coronavirus disease (COVID-19) in China in December 2019 became the epicenter for the spread of a global pandemic. The SARS-CoV-2 coronavirus causes a cascade of respiratory diseases similar to severe acute respiratory syndrome (SARS). Currently, there is no effective, specific, and safe treatment for COVID-19 to suppress the virus in the human body. The present study searched for pharmacological substances with antiviral activity for possible drug repositioning based on experimental and theoretical information in a series of publications on in vitro assays of agents against SARS-CoV-2. An analysis identified 46 well-known pharmaceutical substances that could be used for drug repositioning to create a therapy for COVID-19.

Ejemplares similares